guselkumabinterleukin (IL)-23inflammatory bowel diseaseulcerative colitisNCT04033445UC
…patients (n=313) were randomised (1:1:1) to receive intravenous guselkumab 200 or 400 mg or placebo at weeks 0, 4, and 8. Colon biopsy sam…
1articles mentioning drugs
1drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: interleukin (IL)-23 ×
interleukin (IL)-23
This drug is selected. Its supporting articles are shown below.